Announcements

14 June 2024
Pharmacoepidemiology | Aims and Scope Update

To further enhance the quality of Pharmacoepidemiology (ISSN: 2813-0618) and the papers published in it, under the guidance of our Editor-in-Chief, Dr. Carlotta Franchi, the journal has updated and revised its aims and scope. The original scope and the updated version are listed below.

Scope (new version):

Scope (old version):

Pharmacoepidemiology welcomes manuscripts covering a broad range of areas including, but not limited to, the following:

  • Designs, analyses, results, and interpretations of studies on drugs, biologics, or medical devices;
  • Molecular pharmacoepidemiology;
  • The methodology of pharmacoepidemiology;
  • Pharmacovigilance/preventative pharmacovigilance/ecopharmacovigilance;
  • Patient safety;
  • Pharmacoepidemiology studies in targeted populations and settings;
  • Patterns of drug utilization;
  • Patterns of drug prescription, appropriateness of prescriptions, overprescription;
  • Polypharmacology;
  • Randomized control trials on drugs;
  • Systematic review or meta-analysis related to drugs;
  • Post-marketing surveillance;
  • Pharmacoeconomics;
  • The formulation and interpretation of regulatory guidelines;
  • Studies on the benefits/safety/effectiveness of pharmaceuticals, biologics, or medical devices;
  • Harm/benefit assessments in drug therapy;
  • The evaluation of risk management plans on pharmaceuticals, biologics, and medical devices.

Pharmacoepidemiology welcomes manuscripts covering a broad range of areas including, but not limited to:

  • designs, analyses, results, and interpretations of studies on drugs, biologics, or medical devices;
  • molecular pharmacoepidemiology;
  • the methodology of pharmacoepidemiology;
  • pharmacovigilance;
  • patient safety;
  • patterns of drug utilization;
  • post-marketing surveillance;
  • pharmacoeconomics;
  • the formulation and interpretation of regulatory guidelines;
  • studies on the benefits/safety/effectiveness of pharmaceuticals, biologics, or medical devices;
  • harm/benefit assessments in drug therapy;
  • the evaluation of risk management plans on pharmaceuticals, biologics and medical devices.

For more detailed information, please visit the following link: https://www.mdpi.com/journal/pharmacoepidemiology/about.

Pharmacoepidemiology Editorial Office

More News...
Back to TopTop